TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29722919
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioural therapy (cCBT) program
Study: 21111980
Drug: Low-dose furosemide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5 μg kg(‐1) min(‐1) continuous infusion for 8 hours)
Study: 21111980
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (HDF, 20 mg/h continuous infusion for 8 hours)
Study: 21111980
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (HDF)
Study: 12796139
Drug: Reboxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8 mg)
Study: 8816577
Drug: Single 150-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 150-mg oral dose of fluconazole
Study: 8816577
Drug: Intravaginal antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal antifungal agents
Study: 1384305
Drug: 5-hydroxytryptophan (5-HTP)
Normalized name: 5-hydroxytryptophan (5-HTP) 50 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (5-HTP) 900 mg/d
Study: 3892151
Drug: Initial 18-week
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial 18-week chemotherapy (vincristine, actinomycin D, cyclophosphamide, adriamycin) followed by local therapy (radical surgery or radiation)
Study: 3892151
Drug: Tumor volume
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor volume less than 100 ml
Study: 3892151
Drug: Tumor volume
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor volume greater than or equal to 100 ml
Study: 25694375
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point therapy (G-TPT)
Study: 12297477
Drug: Vit C
Normalized name: M-Vit Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit C (300 mg/d) and Vit E (600 mg/d) for 15 days before BMT
Study: 12297477
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received the same treatment without prior vitamin administration
Study: 10429748
Drug: Fiber supplement
Normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber supplement (20 g/d)
Study: 30898329
Drug: Interactive text
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive text message conversations with Peer Health Educators, plus five daily automated, unidirectional theory-based messages, plus a weekly self-monitoring text message assessment (TXT-PHE; n = 94)
Study: 30898329
Drug: Five daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five daily automated, unidirectional theory-based messages plus a weekly self-monitoring text message assessment (TXT-Auto; n = 99)
Study: 30898329
Drug: Weekly self-monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly self-monitoring text message assessment only (AO; n = 93)
Study: 23792179
Drug: Behavioural Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Activation (BA) and Antidepressant Medication (ADM)
Study: 8142205
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide
Study: 18299686
Drug: Combined angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined angiotensin and angiotensin receptor blockade
Study: 18299686
Drug: Novel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatment options
Study: 15096068
Drug: Smoking reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking reduction during the treatment intervention
Study: 3140748
Drug: Praziquantel (split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (split doses)
Study: 3140748
Drug: Oxamniquine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine (single dose)
Study: 25792830
Drug: Nab-paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (125 mg/m², days 1, 8, and 15) and carboplatin (AUC=2; days 1, 8, and 15) every 21 days for four cycles
Study: 25792830
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m², days 1, 8, and 15) and carboplatin every 21 days for four cycles
Study: 9755356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of selective serotonin reuptake inhibitors with other serotonergic agents
Study: 8091931
Drug: Vaxigrip vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaxigrip vaccine (containing antigens A/Ghizhou/54/89, A/Singapore/6/86, and B/Yamagata/16/88)
Study: 16438370
Drug: Vaxigrip vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaxigrip vaccine
Study: 3291008
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy and radiotherapy (Arm B)
Study: 3291008
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy followed by radiotherapy (Arm A)
Study: 28193657
Drug: Velpatasvir (VEL)
DrugBank: Velpatasvir (DB11613)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Velpatasvir (VEL) administered at doses up to 450 mg
Study: 28193657
Drug: Velpatasvir (VEL)
DrugBank: Velpatasvir (DB11613)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Velpatasvir (VEL) at doses greater than 5 mg
Study: 22011694
Drug: Probucol 250
Normalized name: probucol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 250 mg once daily (QD) after breakfast for 14 days
Study: 22011694
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg once daily (QD) after breakfast for 14 days
Study: 22011694
Drug: Probucol 250
Normalized name: probucol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 250 mg twice a day (b.i.d) after breakfast and dinner for 14 days
Study: 14753248
Drug: Budesonide HFA
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide HFA 400 microg twice daily
Study: 137218
Drug: Fenoterol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.4 mg)
Study: 29913280
Drug: Emricasan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan (25 mg, twice daily for 3 months)
Study: 26331434
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT) combined with intravenous patient-controlled sufentanil analgesia
Study: 19138370
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil cream
Study: 17006735
Drug: Sonographic gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonographic gel application (Group A)
Study: 24255769
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen
Study: 25943647
Drug: 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg Folic Acid (FA) daily for a median of 23 days
Study: 20451683
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor
Study: 10791109
Drug: IL-4 soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-4 soluble receptor (IL-4sR)
Study: 10791109
Drug: Other soluble
Normalized name: others
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other soluble cytokine receptors (IL-6sR, IL-1 beta, TNF-alpha, IL-1sR2, TNF-sR1, TNF-sR2)
Study: 9340503
Drug: Reteplase (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reteplase (10 MU in two bolus doses given 30 minutes apart)
Study: 9340503
Drug: Alteplase (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (up to 100 mg infused over a period of 90 minutes)
Study: 20472116
Drug: celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 400 mg orally
Study: 20705373
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA 1 g daily
Study: 26368562
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation in LGIB patients
Study: 20720348
Drug: Sibutramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine plus L-carnitine
Study: 17631452
Drug: Cardiac cell
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac cell therapy
Study: 15153208
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine (Group L, n = 10)
Study: 9482768
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g maltitol in chocolate
Study: 9482768
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g maltitol in chocolate
Study: 2686416
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g intravenously every eight hours
Study: 31334795
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (n=581) - continuous intravenous insulin targeting blood glucose concentration of 80-130 mg/dL (4.4-7.2 mmol/L)
Study: 31334795
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (n=570) - insulin on a sliding scale targeting blood glucose concentration of 80-179 mg/dL (4.4-9.9 mmol/L)
Study: 28911684
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 2 capsules daily for 12 weeks)
Study: 17602064
Drug: Darbepoetin treatment
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin treatment
Study: 17602064
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sTfR after 2 weeks and hemoglobin after 4 weeks
Study: 14988450
Drug: 500 micro
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micro g FA capsule
Study: 14988450
Drug: 500 micro
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micro g [6S]-5-MTHF capsule
Study: 30294552
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin injections (MDI)
Study: 25406267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of treadmill and lower-limb resistance supervised exercise training for 12 weeks
Study: 16785375
Drug: Methyl aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl aminolevulinate PDT (160 mg/g; n = 96)
Study: 16785375
Drug: Fluorouracil (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (5% cream; n = 30)
Study: 10519330
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) + GnRH analogue
Study: 6754328
Drug: Factor XIII
Normalized name: Factor XIII
DrugBank: Factor XIII (human) (DB12909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor XIII treatment
Study: 6754328
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no factor XIII treatment)
Study: 30153598
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg ketamine
Study: 30670277
Drug: Ginger (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (300 mg)
Study: 30670277
Drug: Frankincense (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frankincense (300 mg)
Study: 12823598
Drug: Interferon-alpha combined
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha combined with ketoprofen (3 million units three times a week and 150 mg twice a day)
Study: 9607830
Drug: nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nelfinavir mesylate (750 mg and 1000 mg three times daily)
Study: 15566422
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg daily for 14 days
Study: 7691342
Drug: Incidental teaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidental teaching procedures; utilized in a multiple-baseline fashion across three sequential environments.
Study: 3084952
Drug: Uncooked cornstarch
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncooked cornstarch (1.4-2.0 g/kg body weight, two doses)
Study: 3084952
Drug: Uncooked cornstarch
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncooked cornstarch (two doses in the morning)
Study: 3084952
Drug: Uncooked cornstarch
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncooked cornstarch (2-3 g/kg body weight every 6 hours)
Study: 29146124
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg
Study: 22301107
Drug: Non-drug-releasing implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug-releasing implants
Study: 21386974
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (50 mg per day)
Study: 7589024
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 mg or 0.25 mg)
Study: 2260872
Drug: High-dose dl-Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dl-Leucovorin (500 mg/m2) and 5-FU (600 mg/m2)
Study: 6768078
Drug: Heroin self-administration
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin self-administration with naltrexone placebo
Study: 16140230
Drug: Supervised home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised home exercise programme (twice-weekly for 6 weeks)
Study: 12096962
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost and 0.5% timolol combination therapy
Study: 12096962
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost monotherapy
Study: 12096962
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol monotherapy
Study: 7798505
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole (25 mg of aspirin and 200 mg of dipyridamole twice daily)
Study: 1902404
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole
Study: 2346545
Drug: Econazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Econazole 1% spray
Study: 3583491
Drug: Fenticonazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole 2% cream
Study: 2346545
Drug: Fenticonazole spray
Normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole spray
Study: 393378
Drug: PACe (Cis-dichlorodiammineplatinum(II)
Normalized name: CIS-DIAMMINEDICHLOROPLATINUM II
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PACe (Cis-dichlorodiammineplatinum(II) 80 mg/m2 iv Day 1, Adriamycin 40 mg/m2 iv Day 1, cyclophosphamide 200 mg/m2 orally Days 2-5)
Study: 29400014
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with oral MPA (400-600 mg/day)
Study: 29400014
Drug: Repeated treatment
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated treatment with oral MPA (400-600 mg/day)
Study: 1960301
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg/day)
Study: 23555538
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day)
Study: 27418597
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus Aspirin
Study: 9431857
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy (one or a combination of two first-line antihypertensive drugs) for 6 months
Study: 9116923
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg)
Study: 8099804
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mg vitamin C)
Study: 30361237
Drug: Probenecid (PROB)
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid (PROB) 1000 mg orally
Study: 30361237
Drug: Probenecid (PROB)
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid (PROB) 1000 mg orally with Furosemide (FSM) 40 mg orally
Study: 30361237
Drug: Furosemide (FSM)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (FSM) 40 mg orally
Study: 28814399
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g soybean oil
Study: 28814399
Drug: 32 g
Normalized name: PEG-32 Glyceryl Laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 g soybean oil
Study: 11744466
Drug: Alfuzosin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 15 mg OD
Study: 10770448
Drug: Sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-200 mg/day)
Study: 8626364
Drug: Nefazodone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone and Sertraline
Study: 29878382
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ixekizumab every 2 weeks
Study: 29878382
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ixekizumab every 4 weeks
Study: 20634300
Drug: Corticosteroids (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (methylprednisolone pulse for 3 days in months 1, 3, and 5, oral prednisone 0.5 mg/kg every other day, azathioprine 1.5 mg/kg per day for 6 months)
Study: 1416418
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion at 3.0 pmol/kg/min
Study: 3933317
Drug: Buccal nitroglycerin
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal nitroglycerin (GTN) 3 mg administered 3 times daily
Study: 3933317
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN) 30 mg administered 4 times daily
Study: 28940681
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education for caregivers and provision of ultrasonic cleaning devices
Study: 15126742
Drug: Otosporin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otosporin (1 mL)
Study: 15126742
Drug: 1% aqueous
Normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% aqueous NCT solution (1 mL)
Study: 3963319
Drug: Oral flunitrazepam
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flunitrazepam
Study: 3963319
Drug: Oral pentobarbital
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentobarbital
Study: 3963318
Drug: Oral NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NaCl solution
Study: 3963319
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine
Study: 3963319
Drug: Intramuscular droperidol/fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular droperidol/fentanyl
Study: 3963318
Drug: Intramuscular NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular NaCl solution
Study: 25914349
Drug: 40 intravesical
Normalized name: valrubicin
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 intravesical BoNT‐A injections (100 U in 10 mL)
Study: 22085338
Drug: High-dosage bevacizumab
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage bevacizumab (15 mg/kg)
Study: 22085338
Drug: Low-dosage bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low-dosage bevacizumab (7.5 mg/kg)
Study: 23683134
Drug: Febuxostat 40
Normalized name: febuxostat 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 40 mg
Study: 19286847
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg
Study: 20370912
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg (200 mg in moderate renal impairment)
Study: 19155521
Drug: HPV-16 L1
Normalized name: HPV 16 E7/HSP65 vaccine
DrugBank: Verpasep caltespen (DB04959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16 L1 VLP vaccine
Study: 10616257
Drug: Individual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual administration of HGSHS:A, TAS, DES, PCI
Study: 10616257
Drug: Group administration
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group administration of HGSHS:A, TAS, DES, PCI
Study: 3728935
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluids